Does Complement Inhibitor Inhibit Both Forms of Macular Degeneration?
September 7, 2009
“POT-4″ (Potentia Pharmaceuticals) a C3 complement inhibitor may be effective against both forms of macular degeneration. The announcement was made at the Asia-Pacific Academy of Ophthalmology and American Academy of Ophthalmology in Nusa Dua, Indonesia. Results of the phase I trials were positive.
While complement activation has been implicated with chronic inflammatory conditions, tissue damage, glaucoma, uveitis, spinal cord injury, trauma, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and pulmonary disease, it may also play a vital role in the pathogenesis of exudative AMD, and perhaps, non-exudative AMD.
The results of the phase I trials showed a favorable safety profile. Although phase I trials are designed for safety, not efficacy, initial results did show some clinical efficacy in that some patients did improve clinically and the vision stablized.
If successful, POT-4 would be delivered locally as an intravitreal injection.
Randall V. Wong, M.D.
www.RetinaEyeDoctor.com
- Acucela Presentations at ARVO 2009
- Advanced Cell Technology, OHSU Researchers Show Safety, Efficacy of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelium (RPE)
- QLT Announces Positive Results from Visudyne-Lucentis Combination Therapy for Wet AMD
- Ophthotech Announces FDA Approval for New anti-PDGF Product
- Dementia and Age-Related Macular Degeneration (AMD) Could Share Similar Pathogenesis
Comments
Jump down to form below to submit your own comments
Subscribe for Free!
